Trial Profile
A Phase II Study of OSI-774 (NSC-718781) in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Aug 2005 New trial record.